Evidence map›Paper›PMID 40761395›Full record

ArticleFrontiers in pharmacology2025

Preclinical pharmacology of alogabat: a novel GABA

Giuseppe Cecere, Theresa M Ballard, Frederic Knoflach, Michael Honer, Joerg F Hipp, Pilar Garces, Thomas Mueggler, Basil Künnecke, Andreas Bruns, Eric P Prinssen and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The role of GABANeuroscience and biobehavioral reviews · 2026
    Review
  2. Article
  3. GABAFrontiers in pharmacology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Giuseppe Cecere *Medicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Theresa M Ballard *Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Frederic Knoflach *Neuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Michael HonerNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Joerg F HippNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Pilar GarcesNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Thomas MuegglerNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Basil KünneckeNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Andreas BrunsNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Eric P PrinssenNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Philipp SchoenenbergerNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Philipp JanzNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Roger RedondoNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Barbara BiemansNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Henner KnustMedicinal Chemistry, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Andrés Olivares-MoralesPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Alessandro BrigoPharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Jan Michael SchulzNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Daniel BertrandHiQScreen Sàrl, Vésenaz, Switzerland.
Michael SaxeNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Eoin C O'ConnorNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Maria-Clemencia HernandezNeuroscience and Rare Diseases, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alterations in the GABAergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Angelman syndrome (AS), particularly in cases involving large deletions in the 15q11-13 region. Positive modulation of GABA Methods: Alogabat was assessed for binding and functional activity at GABA Results: Alogabat is a potent positive allosteric modulator of GABA Conclusion: Alogabat showed beneficial effects in mouse models relevant to neurodevelopmental disorders and anti-seizure activity at doses that did not produce cognitive, sedative, or motoric side effects.

Indexed as

Angelman syndromeautism spectrum disorderbiomarkerelectroencephalographyGABAAGABAA-α5pharmacological MRIpositron emission tomography (PET)

Identifiers

PMID40761395
PMCPMC12319775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.